Clinical Trial Update: A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for GC1102 recombinant hepatitis B immunoglobulin in chronic hepatitis B patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• GC1102 (Hepatitis B immunoglobulin, recombinant)

Snippet

Sponsor: Green Cross Corporation | Conditions: Hepatitis B | Phase 2 | Status: UNKNOWN